Stockreport

Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

Olema Pharmaceuticals, Inc.  (OLMA) 
PDF Pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L metastatic breast cancer on track for top-line data in 2026Pivotal Phase 3 OPERA-02 [Read more]